Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia

NCT07607938 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT07607938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07607938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia
Lead sponsor
NYU Langone Health
Phase
Phase 1
Overall status
Recruiting
Start date
September 30, 2026
Completion date
September 30, 2030
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anhedonia, emotional blunting